Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan liposome + capecitabine + lenvatinib
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This drug combination is a multi-modality therapeutic regimen being evaluated for the second-line treatment of advanced or metastatic biliary tract carcinoma (BTC). It consists of **irinotecan liposome**, a nanoparticle formulation of the topoisomerase I inhibitor irinotecan designed for prolonged systemic exposure and enhanced tumor accumulation; **capecitabine**, an oral fluoropyrimidine carbamate that functions as a cytotoxic prodrug of 5-fluorouracil; and **lenvatinib**, an oral multi-kinase inhibitor targeting VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET. The regimen, studied in clinical trials led by investigator Yunpeng Liu, aims to leverage the synergistic effects of cytotoxic chemotherapy and targeted anti-angiogenic therapy to overcome resistance in refractory biliary tract cancers.
- Other names
- Irinotecan hydrochloride liposome injection + Capecitabine + LenvatinibIrinotecan liposome plus Capecitabine and Lenvatinib
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)TOP1 (DNA Topoisomerase I)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR (FGFR family)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on irinotecan liposome + capecitabine + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan liposome + capecitabine + lenvatinib.